Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
November 19, 2026

FDA approves Regeneron’s Livsayis for generalised myasthenia gravis

The US Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals’ Livsayis (cemdisiran) to treat generalised myasthenia gravis (gMG) in adult patients positive for anti-acetylcholine receptor (AChR) antibodies.

Regeneron manages Livsayis’ manufacturing and commercialisation under a global agreement with Alnylam. Credit: lev radin/Shutterstock.com.